Analysts Viewpoint
ARQT’s latest rating updates from top analysts.
Arcutis Biotherapeutics Inc’s recent filing unveils that its Director Welgus Howard G. unloaded Company’s shares for reported $92616.0 on Oct
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.